Skip to main content

Compare Stocks

Date Range: 

 Champions OncologyCheckmate PharmaceuticalsPluristem TherapeuticsBiomXAyala Pharmaceuticals
SymbolNASDAQ:CSBRNASDAQ:CMPINASDAQ:PSTINYSEMKT:PHGENASDAQ:AYLA
Price Information
Current Price$9.84$6.30$3.82$5.64$10.00
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.82.01.40.61.3
Analysis Score3.53.43.40.03.4
Community Score2.22.52.92.92.7
Dividend Score0.00.00.00.00.0
Ownership Score1.73.30.00.00.0
Earnings & Valuation Score1.90.60.60.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$16.00$24.75$9.88$25.00$24.20
% Upside from Price Target62.60% upside292.86% upside158.51% upside343.26% upside142.00% upside
Trade Information
Market Cap$131.76 million$136.24 million$121.25 million$131.13 million$132.41 million
Beta1.2N/A2.530.48N/A
Average Volume30,44947,205643,37525,23629,077
Sales & Book Value
Annual Revenue$32.12 millionN/A$20,000.00N/A$2.33 million
Price / Sales4.10N/A6,062.34N/A56.83
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.45 per shareN/A$2.20 per share$3.83 per shareN/A
Price / Book21.87N/A1.74N/A
Profitability
Net Income$-1,980,000.00$-28,290,000.00$-29,150,000.00$-20,560,000.00$-17,790,000.00
EPS($0.17)N/AN/A($3.66)N/A
Trailing P/E RatioN/A0.000.00N/A0.00
Forward P/E Ratio65.60N/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-4.18%N/AN/AN/A-850.81%
Return on Equity (ROE)-29.93%N/A-86.51%-39.95%-625.24%
Return on Assets (ROA)-7.41%-57.12%-68.23%-36.65%-70.31%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio1.18%16.26%5.12%13.87%8.63%
Quick Ratio1.18%16.26%5.12%13.87%8.63%
Ownership Information
Institutional Ownership Percentage52.84%75.64%11.95%26.78%12.81%
Insider Ownership Percentage46.80%N/A4.90%23.20%N/A
Miscellaneous
Employees143221469534
Shares Outstanding13.39 million21.63 million31.74 million23.25 million13.24 million
Next Earnings Date7/26/2021 (Estimated)9/17/2021 (Estimated)N/AN/A8/12/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableNot OptionableNot Optionable
SourceHeadline
Ayala Pharmaceuticals (NASDAQ:AYLA) Issues Quarterly  Earnings Results, Misses Expectations By $0.03 EPSAyala Pharmaceuticals (NASDAQ:AYLA) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPS
americanbankingnews.com - May 15 at 12:22 PM
Ayala Pharmaceuticals Inc (AYLA)Ayala Pharmaceuticals Inc (AYLA)
investing.com - May 15 at 12:34 AM
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q1 Loss, Misses Revenue EstimatesAyala Pharmaceuticals, Inc. (AYLA) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 14 at 2:22 PM
Ayala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business UpdateAyala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
finance.yahoo.com - May 14 at 9:21 AM
Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) Short Interest UpdateAyala Pharmaceuticals, Inc. (NASDAQ:AYLA) Short Interest Update
americanbankingnews.com - May 2 at 5:16 AM
Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) Given Average Rating of "Buy" by BrokeragesAyala Pharmaceuticals, Inc. (NASDAQ:AYLA) Given Average Rating of "Buy" by Brokerages
americanbankingnews.com - May 1 at 4:34 AM
Ayala Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of AL102 in Combination with BCMA Targeting Agent, WVT078, in Patients with relapsed/refractory Multiple MyelomaAyala Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of AL102 in Combination with BCMA Targeting Agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma
finance.yahoo.com - April 21 at 12:34 PM
Ayala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business UpdateAyala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business Update
finance.yahoo.com - March 25 at 9:10 AM
Ayala Pharmaceuticals Inc (AYLA) President & CEO Roni Mamluk Sold $617,137 of SharesAyala Pharmaceuticals Inc (AYLA) President & CEO Roni Mamluk Sold $617,137 of Shares
finance.yahoo.com - February 24 at 11:15 PM
Ayala Pharmaceuticals raises $25M from private stock saleAyala Pharmaceuticals raises $25M from private stock sale
bizjournals.com - February 24 at 6:15 PM
Ayala Pharmaceuticals To Raise $25M Via Private Stock Placement; Shares Pop 16%Ayala Pharmaceuticals To Raise $25M Via Private Stock Placement; Shares Pop 16%
finance.yahoo.com - February 22 at 1:13 PM
Ayala Pharmaceuticals Raises $25M Via Equity To Fund AL102 Development In Connective Tissue TumorsAyala Pharmaceuticals Raises $25M Via Equity To Fund AL102 Development In Connective Tissue Tumors
finance.yahoo.com - February 19 at 2:34 PM
Companies Like Ayala Pharmaceuticals (NASDAQ:AYLA) Are In A Position To Invest In GrowthCompanies Like Ayala Pharmaceuticals (NASDAQ:AYLA) Are In A Position To Invest In Growth
finance.yahoo.com - February 19 at 9:33 AM
ACIU & Alzheimers Vaccine, GNMK Rallies, ESSAs Prostate Cancer Drug On Track, MNPR On WatchACIU & Alzheimer's Vaccine, GNMK Rallies, ESSA's Prostate Cancer Drug On Track, MNPR On Watch
nasdaq.com - February 12 at 7:35 AM
NVAXs Covid Jab Shows 89.3% Efficacy In UK Trial, AZRX Awaits Data, FDA Lifts Hold On BLCM TrialNVAX's Covid Jab Shows 89.3% Efficacy In UK Trial, AZRX Awaits Data, FDA Lifts Hold On BLCM Trial
nasdaq.com - January 29 at 2:14 AM
Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 ...Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 ...
apnews.com - January 28 at 11:10 AM
Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast CancerAyala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast Cancer
finance.yahoo.com - January 28 at 11:10 AM
Ayala Pharmaceuticals to Present at Noble Capital Markets 17th Annual Small & Microcap ...Ayala Pharmaceuticals to Present at Noble Capital Markets 17th Annual Small & Microcap ...
apnews.com - January 13 at 8:55 PM
Ayala Pharmaceuticals to Present at Noble Capital Markets 17th Annual Small & Microcap Virtual Investor ConferenceAyala Pharmaceuticals to Present at Noble Capital Markets 17th Annual Small & Microcap Virtual Investor Conference
finance.yahoo.com - January 13 at 8:55 PM
Ayala Pharmaceuticals to Present at the Virtual H.C. Wainwright Bioconnect ConferenceAyala Pharmaceuticals to Present at the Virtual H.C. Wainwright Bioconnect Conference
finance.yahoo.com - January 5 at 11:57 AM
Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in ...Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in ...
omaha.com - January 4 at 10:54 PM
Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in Pivotal Phase 2/3 StudyAyala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in Pivotal Phase 2/3 Study
finance.yahoo.com - January 4 at 12:53 PM
Ayala Pharmaceuticals IncAyala Pharmaceuticals Inc
reuters.com - December 16 at 7:44 AM
Is Ayala Pharmaceuticals, Inc. (AYLA) A Good Stock To Buy?Is Ayala Pharmaceuticals, Inc. (AYLA) A Good Stock To Buy?
feedproxy.google.com - November 26 at 9:12 PM
Growth Investors: Industry Analysts Just Upgraded Their Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) Revenue Forecasts By 64%Growth Investors: Industry Analysts Just Upgraded Their Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) Revenue Forecasts By 64%
nasdaq.com - November 20 at 10:08 AM
DateCompanyBrokerageAction
3/22/2021Champions OncologyRoth CapitalBoost Price Target
11/27/2019Champions OncologyBenchmarkInitiated Coverage
7/24/2019Champions OncologyJanney Montgomery ScottDowngrade
2/27/2019Champions OncologyNational SecuritiesInitiated Coverage
7/17/2018Champions OncologyCraig HallumInitiated Coverage
3/19/2021Checkmate PharmaceuticalsJefferies Financial GroupLower Price Target
9/1/2020Checkmate PharmaceuticalsBank of AmericaInitiated Coverage
9/1/2020Checkmate PharmaceuticalsBMO Capital MarketsInitiated Coverage
9/1/2020Checkmate PharmaceuticalsBTIG ResearchInitiated Coverage
5/10/2021Pluristem TherapeuticsAlliance Global PartnersInitiated Coverage
12/7/2020Pluristem TherapeuticsHC WainwrightReiterated Rating
10/9/2020Pluristem TherapeuticsDawson JamesReiterated Rating
5/15/2020Pluristem TherapeuticsMaxim GroupReiterated Rating
7/22/2019Pluristem TherapeuticsLADENBURG THALM/SH SHInitiated Coverage
1/9/2020BiomXCantor FitzgeraldReiterated Rating
1/25/2021Ayala PharmaceuticalsNoble FinancialReiterated Rating
8/13/2020Ayala PharmaceuticalsRaymond JamesReiterated Rating
8/13/2020Ayala PharmaceuticalsOppenheimerReiterated Rating
6/2/2020Ayala PharmaceuticalsCitigroupInitiated Coverage
(Data available from 5/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.